GILDKite, A Gilead CompanyFinished
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
Relapsed or Refractory Large B-cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 35 (final count)
- Started
- Aug 9, 2022
- Main results expected
- Nov 24, 2025
- Fully finished
- Nov 24, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage and Severity of Participants with Treatment-emergent Cytokine Release Syndrome (CRS) and Neurologic Events
Measured over: Up to 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05459571 · record last updated 2026-02-02 · checked 2026-11-09 15:47 UTC